The short version
Selank and Semax are two short synthetic peptides, each derived from a natural regulatory molecule: Selank from tuftsin, an immunomodulatory fragment, and Semax from corticotropin ACTH(4-10). Both were designed in the 1980s-1990s within the same Russian scientific school, at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, in collaboration with the Institute of Pharmacology. Their structural commonality is striking: each adds, to a biologically active fragment, the same stabilising tripeptide, Pro-Gly-Pro, intended to slow enzymatic degradation.
The literature associates them with distinct properties. Selank is studied mainly as an anxiolytic and modulator of neurotransmission, with work focusing on the GABA system and the neurotrophic factor BDNF. Semax is studied for its described effects on cognition, neuroprotection and, here too, BDNF expression. On the regulatory side, the picture is contrasting: both are registered as medicines in Russia, but neither is approved by the US FDA or the European EMA.
The most important point to keep in mind is the actual state of the evidence. Most of the published data come from small Russian trials and preclinical studies, with little independent replication by Western laboratories. This article reports that literature with its limits; it is neither medical advice, nor a therapeutic claim, nor an encouragement to use. Products sold under Research Use Only (RUO) status are reserved for laboratory research.
A shared origin: the Moscow school of regulatory peptides
Selank and Semax cannot be understood apart from their context of origin. They are the product of a Soviet, then Russian, line of research devoted to regulatory peptides: short amino-acid sequences derived from endogenous molecules, conceived as messengers able to modulate brain functions without the effects of heavier chemical syntheses. The teams at the Institute of Molecular Genetics in Moscow, around Nikolai Myasoedov and colleagues, played a central role in this approach.
The design strategy is consistent across the two molecules. One starts from a short fragment of a natural protein believed to carry a biological activity, then grafts on a protective motif to improve its stability. In both cases, that motif is the C-terminal tripeptide Pro-Gly-Pro, which slows the action of peptidases and prolongs the molecule's half-life. This shared design explains why the two peptides are so often presented together.
One must, however, distinguish the scientific history from commercial promotion. The fact that these peptides come from an identifiable, documented research programme says nothing, in itself, about the strength of the efficacy evidence. A molecule can have a respectable academic origin and a still-limited clinical database. That is precisely the case here, and it is what the rest of this article sets out to clarify.
Selank: a stabilised derivative of tuftsin
Selank is a heptapeptide derived from tuftsin, a natural tetrapeptide (Thr-Lys-Pro-Arg) arising from a region of the immunoglobulin heavy chain and known for its immunomodulatory properties. By adding the tripeptide Pro-Gly-Pro to the tuftsin sequence, researchers obtained a more stable molecule, studied no longer only for immunity but also for its described effects on anxiety and behaviour.
The Russian literature positions Selank as a peptide anxiolytic, studied notably in generalised anxiety disorder and neurasthenia. An often-cited trial (Zozulia and colleagues, 2008) reports efficacy comparable to that of a reference benzodiazepine, medazepam, with a different effect profile. This work remains observations to be confirmed: it involves modest sample sizes and has not been the subject of large-scale independent replications outside Russia.
Beyond anxiety, preclinical studies have explored other avenues, including memory. A study in rats (Kolik and colleagues, 2019) describes an effect of Selank on BDNF regulation in the hippocampus and prefrontal cortex in a model of ethanol-related memory impairment. These results are mechanistically interesting, but they belong to animal research and cannot be transposed directly to humans.
Semax: a fragment of ACTH(4-10)
Semax is a heptapeptide built from the ACTH(4-7) sequence of corticotropin, to which the stabilising tripeptide Pro-Gly-Pro is again added. Unlike the full ACTH hormone, this fragment is devoid of corticotropic hormonal activity: it was designed to retain certain described actions on the central nervous system without stimulating cortisol production. It is this decoupling that steered its study toward cognition and neuroprotection.
One of the most cited studies (Dolotov and colleagues, Brain Research, 2006) reports that Semax regulates the expression of BDNF and its receptor trkB in the rat hippocampus. As BDNF is a key factor in synaptic plasticity and neuronal survival, this result fed the hypothesis of a neurotrophic mechanism. Other preclinical work has examined neuroprotective effects in models of experimental cerebral ischaemia, describing a reduction in damage and memory deficits in animals.
In Russia, Semax has also been studied clinically, notably in the setting of ischaemic stroke and cognitive disorders. Here again, these trials are mostly limited in size and published in Russian journals, which raises the question of their reproducibility and their evaluation by independent teams. Consistency between preclinical data and clinical signals is a favourable point, but it does not replace large randomised trials.
Studied mechanisms: GABA, BDNF and neurotransmission
The mechanisms proposed for Selank revolve in part around the GABAergic system, the brain's main inhibitory system. An in vitro study (Filatova and colleagues, Frontiers in Pharmacology, 2017) tested the effect of Selank on the expression of GABAergic neurotransmission genes in neuroblastoma cells. Notably, Selank alone did not change the expression of these genes, but it markedly attenuated the changes induced by GABA, suggesting a possible action on the interaction between GABA and its receptors rather than a direct transcriptional effect.
For Semax, the described mechanisms include modulation of neurotransmission systems and, above all, regulation of neurotrophins. Work by the Moscow group describes a dose-dependent modulation of the binding of neurotransmitters such as acetylcholine and GABA on neuronal membranes, along with the effect on BDNF and trkB already mentioned. Some authors have also observed that Semax and Selank inhibit enzymes that degrade enkephalins, which could prolong the action of endogenous opioid peptides.
These mechanisms are biologically plausible and documented in vitro as well as in animals. Essential caution is nonetheless required: showing that a peptide modulates a signalling pathway in an experimental model does not prove that it will produce a measurable, safe benefit in humans. Mechanistic plausibility is a starting point for research, never proof of clinical efficacy in itself.
Regulatory status: a marked contrast
The regulatory status of Selank and Semax illustrates well how much an approval depends on the national framework. In Russia, both peptides are registered as medicines and appear on the list of essential medicines: Semax is used in neurological and cognitive indications, Selank as an anxiolytic. This registration rests on the files of trials conducted locally.
Conversely, neither Selank nor Semax is approved by the Food and Drug Administration in the United States or by the European Medicines Agency. No major Western authority has validated their efficacy and safety according to its own evaluation standards. This divergence does not mechanically mean that the molecules 'work' on one side and 'not' on the other: it mainly reflects differences in regulatory dossiers, submitted data and methodological requirements.
For a supplier operating under Research Use Only status, this reality is structuring. The products offered are neither medicines nor supplements and must not be administered to humans or animals outside a supervised research setting. Reporting the existence of a Russian approval is a fact; inferring a use recommendation from it would be a claim, which we refuse to make.
What the literature does — and does not — say
This is where rigour is most necessary. The documentary base for Selank and Semax exists and is not negligible: there are consistent preclinical studies, described mechanisms and Russian clinical trials. But several methodological limits recur and must be stated clearly.
First, sample size. Many Russian clinical trials involve dozens of participants, rarely hundreds, which limits statistical power and the ability to detect modest effects or rare risks. Second, replication. A significant share of the data comes from a relatively narrow circle of teams linked to the original programme; confirmations by independent laboratories, particularly Western ones, remain limited. Third, access and language: many publications are in Russian, sometimes hard to evaluate in detail, which complicates international meta-analyses.
Two symmetrical temptations must therefore be resisted. The first would be to reject wholesale a literature that contains real signals and plausible mechanisms. The second, more common in marketing, would be to present these signals as established certainties. The honest reading lies between the two: promising but still fragile data, calling for larger, randomised and replicated trials before any firm conclusion.
Selank and Semax compared
Comparing the two molecules highlights as many similarities as differences. In terms of design, they are almost twins: same laboratory of origin, same stabilisation strategy via Pro-Gly-Pro, same short-heptapeptide format. This kinship explains why they are so often studied and presented in tandem, as a Russian nootropic 'duo'.
In terms of parent molecule and studied effects, they diverge clearly. Selank descends from tuftsin, with an orientation toward immunomodulation and above all anxiety; Semax descends from ACTH(4-10), with an orientation toward cognition and neuroprotection. The most interesting point of convergence is BDNF: both peptides have been the subject of work describing a modulation of this neurotrophic factor, suggesting a possible shared mechanism, but through different pathways and in different contexts.
The idea that they are 'complementary' and would benefit from being combined is, in the current state of knowledge, a hypothesis more than a demonstration. No robust clinical data allow anyone to claim that a combination would be more effective, or even as safe, as each molecule studied separately. The assumed complementarity is inferred from their individual profiles, not proven by dedicated trials.
Current research directions and open questions
Contemporary research on these peptides explores several directions. On the mechanistic side, molecular-biology and transcriptomic approaches seek to map more finely the genes and pathways modulated by Selank and Semax, beyond behavioural observations. This work, often led by the teams of origin, aims to understand how such short sequences can produce central effects.
On the translational side, the open questions are clear. The first is independent replication: trials designed and conducted outside the historical programme, with standardised protocols and published in international peer-reviewed journals, would considerably strengthen the level of evidence. The second concerns pharmacokinetics and long-term safety, still incompletely characterised by Western standards. The third bears on rigorous comparison with reference treatments in trials of sufficient size.
In short, Selank and Semax are legitimate research objects, with a documented scientific history and plausible mechanisms, but backed by a still relatively weak evidence base against Western requirements. The honest answer to the question that opens this article is therefore nuanced: the literature describes interesting signals and coherent mechanisms, while leaving the essential clinical questions without firm answers. It is this nuance, not the promise, that deserves to be conveyed.
Sources
- Dolotov et al., Brain Research, 2006 (Semax regulates BDNF and trkB in the rat hippocampus)
- Kolik et al., Bull Exp Biol Med, 2019 (Selank, tuftsin analogue, and BDNF)
- Filatova et al., Frontiers in Pharmacology, 2017 (GABA, Selank and GABAergic neurotransmission)
- Zozulia et al., 2008 (Selank trial in generalised anxiety disorder and neurasthenia)
- Semax, neuroprotective and antiamnesic effects in experimental cerebral ischaemia (2007)
- Vyunova et al., J Labelled Comp Radiopharm, 2019 (regulatory peptide mechanisms, [3H]GABA binding)
- Semax and Selank inhibit enkephalin-degrading enzymes (Russ J Bioorg Chem)